CANDEL THERAPEUTICS, INC. — Income Charts
23 quarters of history · ending 2025-12-31 · SEC EDGAR
Revenue↑+229.0% +$71K
$102K
R&D↑+128.9% +$6M
$11M
D&A↓-33.5% -$82K
$163K
Operating Income↓-50.8% -$4M
$-13M
EBITDA↓-33.5% -$82K
$163K
Interest Expense↑+263.1% +$1M
$1M
Tax Provision
$0
Net Income↓-5.9% -$623K
$-11M
Operating Margin↑+19543.0pts
-9444.1%
Net Margin↓-5803.2pts
-8622.5%